Management of pediatric hepatocellular carcinoma: A multimodal approach

Mira A. Kohorst, Deepti M. Warad, Jane M. Matsumoto, Julie K. Heimbach, Mounif El-Youssef, Carola A.S. Arndt, Vilmarie Rodriguez, Amulya A. Nageswara Rao

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

HCC is rare in the pediatric population, but is the second most common liver malignancy in children. Survival rates for primary unresectable HCC have been dismal. The objective of this study was to describe our experience with a multimodal approach for the management of unresectable HCC in two adolescent patients and to review the literature. Both patients are currently alive with no recurrence at 51 and 29 months post-transplant. Multimodality treatment involving chemotherapy with doxorubicin, cisplatin, and sorafenib; TACE; timely liver transplantation; and post-transplant therapy with sorafenib and mTOR inhibitors may help improve outcomes and prolong survival in pediatric patients with unresectable HCC.

Original languageEnglish (US)
JournalPediatric Transplantation
DOIs
StateAccepted/In press - 2017

Keywords

  • Chemoembolization
  • Hepatocellular carcinoma
  • Liver transplant
  • Pediatric
  • Sorafenib

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Transplantation

Fingerprint Dive into the research topics of 'Management of pediatric hepatocellular carcinoma: A multimodal approach'. Together they form a unique fingerprint.

  • Cite this

    Kohorst, M. A., Warad, D. M., Matsumoto, J. M., Heimbach, J. K., El-Youssef, M., Arndt, C. A. S., Rodriguez, V., & Nageswara Rao, A. A. (Accepted/In press). Management of pediatric hepatocellular carcinoma: A multimodal approach. Pediatric Transplantation. https://doi.org/10.1111/petr.13007